PharmOptima
Michigan CRO offering in vivo ADME and pharmacokinetics, LC-MS/MS bioanalysis and biochemistry, with a niche in ocular drug development.
About DMPK & ADME
Drug metabolism and pharmacokinetics (DMPK) work describes how a compound is absorbed, distributed, metabolized and excreted (ADME), and how exposure changes with dose, route and species. It guides candidate selection in discovery, then supports dose and species selection for toxicology.
In vitro ADME assays such as metabolic stability, plasma protein binding, permeability and CYP inhibition screen compounds quickly and flag drug-drug interaction risk. In vivo PK studies, often in cannulated rodents and then a non-rodent species, measure exposure directly. Metabolite identification shows whether the toxicology species form the same metabolites as humans, and toxicokinetics confirms exposure within the toxicology studies themselves.
Every DMPK result depends on the bioanalytical method behind it, so ask where samples are analyzed and how methods are qualified.
DMPK and ADME CROs
Showing 18 CROs. Order rotates daily so no lab is permanently listed first.
Laxai Life Sciences
Hyderabad discovery services company offering biology and DMPK support alongside chemistry.
Biotoxtech
Korean non-clinical CRO offering IND and NDA-enabling GLP toxicology, including general, reproductive and genetic toxicity, carcinogenicity and safety pharmacology, with NHP capacity through its group companies.
Accelera
Non-clinical CRO near Milan and part of the NMS Group, offering GLP safety assessment and toxicology, safety pharmacology and preclinical regulatory consulting to move candidates toward IND/CTA.
Jubilant Biosys
Indian integrated drug discovery CRO offering in vivo pharmacology and DMPK alongside chemistry and biology.
QuBEST Bio
Korean nonclinical CRO providing early PK, TK and bioanalytical method development and sample analysis.
Selvita
Polish drug discovery CRO providing integrated chemistry, biology, DMPK and translational research services.
Sai Life Sciences
Integrated CRO-CDMO in India whose discovery biology group provides in vivo pharmacology, DMPK and bioanalysis for small molecule programs.
Southern Research
Not-for-profit research institute in Birmingham, Alabama providing contract drug discovery and preclinical development, including infectious disease and BSL-3 work, oncology models, ADME, bioanalysis, toxicology and…
Anthem Biosciences
Bengaluru CRDMO offering discovery services including DMPK, safety and bioanalysis alongside development and manufacturing.
PhoenixBio
Japanese company offering humanized-liver mice and contract studies for human metabolism, DMPK and hepatitis research.
Nuvisan
German CRO offering integrated discovery, DMPK, bioanalysis and early development services across sites in Germany and France.
Biomere
Biomere (a JOINN company) is a preclinical CRO based in Worcester, MA. Services include non-GLP PK/PD, discovery toxicology, surgical services, disease models, and laboratory sciences. Surgical services include…
Aragen Life Sciences
Integrated discovery and development services company in India offering in vivo pharmacology, DMPK, bioanalysis and safety assessment alongside chemistry and biologics services.
Sygnature Discovery
Integrated drug discovery CRO in Nottingham with in vivo pharmacology, DMPK and bioanalysis alongside chemistry and biology.
Pharmacelsus
German DMPK CRO offering in vitro ADME, in vivo pharmacokinetics and bioanalysis for discovery and early development.
Agilex Biolabs
Australian bioanalytical and toxicology CRO with OECD GLP labs, supporting nonclinical toxicology and clinical bioanalysis.
Axis Bio (QIMA Life Sciences)
Preclinical CRO in Northern Ireland, part of QIMA Life Sciences, running non-GLP rodent PK, dose range finding, biodistribution and disease model studies.
Questions to ask when choosing a DMPK & ADME CRO
- Which in vitro ADME assays do you run in-house, and with which species' matrices and hepatocytes?
- Do you use cannulated animals for serial PK sampling, and in which species?
- Is bioanalysis done on site, and what is the turnaround from last sample to PK report?
- Can you compare metabolite profiles across species to support toxicology species selection?
DMPK & ADME CRO FAQs
Which CROs can run DMPK studies?
Most labs listed here run at least part of a DMPK package: in vitro ADME screening (metabolic stability, permeability, protein binding, CYP inhibition and induction), in vivo pharmacokinetics in rodents and non-rodents, metabolite identification and toxicokinetics within toxicology studies. Check that the lab has bioanalysis in house or a set partner, because turnaround on sample analysis often decides how fast a PK study reports.
Which preclinical partners offer NHP in vivo PK studies?
NHP pharmacokinetics needs access to a primate colony, which has been the main constraint in recent years because of limited cynomolgus supply. Ask whether the lab uses naive or non-naive animals, how many it can assign on your timeline, which routes and sampling schedules it supports (including serial CSF sampling for CNS programs), and whether animals can be reused after a washout period.
CROs working with cynomolgus monkeys →
What is the difference between pharmacokinetics and toxicokinetics?
Pharmacokinetics (PK) describes how a drug is absorbed, distributed, metabolized and eliminated, usually in standalone studies at pharmacologically relevant doses. Toxicokinetics (TK) measures exposure within toxicology studies, at toxicological doses, to link any findings to systemic exposure and to support safety margins for the first clinical dose.